Literature DB >> 20731676

New epitopes and function of anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjögren's syndrome.

H Tsuboi1, I Matsumoto, E Wakamatsu, Y Nakamura, M Iizuka, T Hayashi, D Goto, S Ito, T Sumida.   

Abstract

M3 muscarinic acetylcholine receptor (M3R) plays a crucial role in the secretion of saliva from salivary glands. It is reported that some patients with Sjögren's syndrome (SS) carried inhibitory autoantibodies against M3R. The purpose of this study is to clarify the epitopes and function of anti-M3R antibodies in SS. We synthesized peptides encoding the extracellular domains of human-M3R including the N-terminal region and the first, second and third extracellular loops. Antibodies against these regions were examined by enzyme-linked immunosorbent assay in sera from 42 SS and 42 healthy controls. For functional analysis, human salivary gland (HSG) cells were preincubated with immunoglobulin G (IgG) separated from sera of anti-M3R antibody-positive SS, -negative SS and controls for 12 h. After loading with Fluo-3, HSG cells were stimulated with cevimeline hydrochloride, and intracellular Ca(2+) concentrations [(Ca(2+) )i] were measured. Antibodies to the N-terminal, first, second and third loops were detected in 42·9% (18 of 42), 47·6% (20 of 42), 54·8% (23 of 42) and 45·2% (19 of 42) of SS, while in 4·8% (two of 42), 7·1% (three of 42), 2·4% (one of 42) and 2·4% (one of 42) of controls, respectively. Antibodies to the second loop positive SS-IgG inhibited the increase of (Ca(2+) )i induced by cevimeline hydrochloride. Antibodies to the N-terminal positive SS-IgG and antibodies to the first loop positive SS-IgG enhanced it, while antibodies to the third loop positive SS-IgG showed no effect on (Ca(2+) )i as well as anti-M3R antibody-negative SS-IgG. Our results indicated the presence of several B cell epitopes on M3R in SS. The influence of anti-M3R antibodies on salivary secretion might differ based on these epitopes.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20731676      PMCID: PMC2990929          DOI: 10.1111/j.1365-2249.2010.04188.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Muscarinic acetylcholine receptor autoantibodies in patients with Sjögren's syndrome.

Authors:  Y Naito; I Matsumoto; E Wakamatsu; D Goto; T Sugiyama; R Matsumura; S Ito; A Tsutsumi; T Sumida
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

Review 2.  Antimuscarinic antibodies in Sjögren's syndrome: where are we, and where are we going?

Authors:  Luke Dawson; Andrew Tobin; Peter Smith; Tom Gordon
Journal:  Arthritis Rheum       Date:  2005-10

3.  Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3(213-228) in primary Sjogren's syndrome.

Authors:  L Kovács; I Marczinovits; A György; G K Tóth; L Dorgai; J Pál; J Molnár; G Pokorny
Journal:  Rheumatology (Oxford)       Date:  2005-05-11       Impact factor: 7.580

4.  Multiple residues in the second extracellular loop are critical for M3 muscarinic acetylcholine receptor activation.

Authors:  Marco Scarselli; Bo Li; Soo-Kyung Kim; Jürgen Wess
Journal:  J Biol Chem       Date:  2007-01-09       Impact factor: 5.157

5.  A peptide of human muscarinic acetylcholine receptor 3 is antigenic in primary Sjogren's syndrome.

Authors:  Ilona Marczinovits; László Kovács; Andrea György; Gábor K Tóth; László Dorgai; János Molnár; Gyula Pokorny
Journal:  J Autoimmun       Date:  2005-01-20       Impact factor: 7.094

Review 6.  The histopathology of Sjögren's syndrome in labial salivary gland biopsies.

Authors:  J S Greenspan; T E Daniels; N Talal; R A Sylvester
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1974-02

7.  Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells.

Authors:  L J Dawson; J Stanbury; N Venn; B Hasdimir; S N Rogers; P M Smith
Journal:  Arthritis Rheum       Date:  2006-04

8.  Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjögren's syndrome patients by use of a transfected cell line assay.

Authors:  Juehua Gao; Seunghee Cha; Roland Jonsson; Jeffrey Opalko; Ammon B Peck
Journal:  Arthritis Rheum       Date:  2004-08

9.  Human primary Sjögren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors.

Authors:  S R Bacman; A Berra; L Sterin-Borda; E S Borda
Journal:  Curr Eye Res       Date:  1998-12       Impact factor: 2.424

10.  Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjögren's syndrome.

Authors:  D Cavill; S A Waterman; T P Gordon
Journal:  Scand J Immunol       Date:  2004-03       Impact factor: 3.487

View more
  18 in total

1.  Candidate chromosome 1 disease susceptibility genes for Sjogren's syndrome xerostomia are narrowed by novel NOD.B10 congenic mice.

Authors:  Patricia K A Mongini; Jill M Kramer; Tomo-O Ishikawa; Harvey Herschman; Donna Esposito
Journal:  Clin Immunol       Date:  2014-03-29       Impact factor: 3.969

2.  M3 muscarinic acetylcholine receptor-reactive Th17 cells in primary Sjögren's syndrome.

Authors:  Saori Abe; Hiroto Tsuboi; Hanae Kudo; Hiromitsu Asashima; Yuko Ono; Fumika Honda; Hiroyuki Takahashi; Mizuki Yagishita; Shinya Hagiwara; Yuya Kondo; Isao Matsumoto; Takayuki Sumida
Journal:  JCI Insight       Date:  2020-08-06

Review 3.  Autoantibodies as Endogenous Modulators of GPCR Signaling.

Authors:  Meredith A Skiba; Andrew C Kruse
Journal:  Trends Pharmacol Sci       Date:  2020-12-24       Impact factor: 14.819

4.  RORγt antagonist suppresses M3 muscarinic acetylcholine receptor-induced Sjögren's syndrome-like sialadenitis.

Authors:  M Tahara; H Tsuboi; S Segawa; H Asashima; M Iizuka-Koga; T Hirota; H Takahashi; Y Kondo; M Matsui; I Matsumoto; T Sumida
Journal:  Clin Exp Immunol       Date:  2016-10-11       Impact factor: 4.330

5.  Pelvic floor dysfunction in female Sjögren's syndrome: an 8-year audit.

Authors:  Aaron K Budden; Nèvine I D Te West; Allan D Sturgess; Kate H Moore
Journal:  Int Urogynecol J       Date:  2016-03-10       Impact factor: 2.894

6.  Serologic features of primary Sjögren's syndrome: clinical and prognostic correlation.

Authors:  Mario García-Carrasco; Claudia Mendoza-Pinto; César Jiménez-Hernández; Mario Jiménez-Hernández; Arnulfo Nava-Zavala; Carlos Riebeling
Journal:  Int J Clin Rheumtol       Date:  2012-12

7.  Muscarinic type 3 receptor autoantibodies are associated with anti-SSA/Ro autoantibodies in Sjögren's syndrome.

Authors:  Jian Zuo; Adrienne E G Williams; Yun-Jong Park; Kevin Choi; Annie L Chan; Westley H Reeves; Michael R Bubb; Yun Jong Lee; Kyungpyo Park; Carol M Stewart; Seunghee Cha
Journal:  J Immunol Methods       Date:  2016-07-25       Impact factor: 2.303

8.  Younger patients with primary Sjögren's syndrome are more likely to have salivary IgG anti-muscarinic acetylcholine receptor type 3 antibodies.

Authors:  K Jayakanthan; J Ramya; Santosh Kumar Mandal; P Sandhya; M Gowri; Debashish Danda
Journal:  Clin Rheumatol       Date:  2016-01-26       Impact factor: 2.980

9.  A novel luminescence-based method for the detection of functionally active antibodies to muscarinic acetylcholine receptors of the M3 type (mAchR3) in patients' sera.

Authors:  B Preuss; S Tunaru; J Henes; S Offermanns; R Klein
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

10.  Early BAFF receptor blockade mitigates murine Sjögren's syndrome: Concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction.

Authors:  Arjun Sharma; Jeremy Kiripolsky; Ekaterina Klimatcheva; Alan Howell; Farzad Fereidouni; Richard Levenson; Thomas L Rothstein; Jill M Kramer
Journal:  Clin Immunol       Date:  2016-01-28       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.